Parsons Capital Management Inc. RI Decreases Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Parsons Capital Management Inc. RI lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,275 shares of the company’s stock after selling 125 shares during the period. Parsons Capital Management Inc. RI’s holdings in IDEXX Laboratories were worth $285,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IDXX. Norges Bank purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $148,632,000. FMR LLC grew its position in shares of IDEXX Laboratories by 120.7% during the fourth quarter. FMR LLC now owns 561,266 shares of the company’s stock valued at $104,407,000 after purchasing an additional 306,919 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Principal Financial Group Inc. now owns 787,832 shares of the company’s stock valued at $146,551,000 after purchasing an additional 291,795 shares in the last quarter. BlackRock Inc. grew its position in shares of IDEXX Laboratories by 4.6% during the fourth quarter. BlackRock Inc. now owns 6,549,022 shares of the company’s stock valued at $1,218,251,000 after purchasing an additional 289,208 shares in the last quarter. Finally, Samlyn Capital LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $28,597,000. Institutional investors and hedge funds own 87.46% of the company’s stock.

A number of brokerages have recently weighed in on IDXX. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 7th. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price target for the company in a report on Friday, May 3rd. Finally, Canaccord Genuity increased their price target on shares of IDEXX Laboratories from $255.00 to $260.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. IDEXX Laboratories currently has a consensus rating of “Buy” and a consensus target price of $253.50.

NASDAQ IDXX traded up $1.05 during trading on Wednesday, hitting $250.38. The stock had a trading volume of 305,584 shares, compared to its average volume of 509,357. The company has a debt-to-equity ratio of 14.81, a current ratio of 1.01 and a quick ratio of 0.74. The company has a market cap of $21.39 billion, a P/E ratio of 58.77 and a beta of 0.97. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.13. The business had revenue of $576.06 million during the quarter, compared to the consensus estimate of $575.04 million. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.01 earnings per share. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 4.82 EPS for the current year.

In other news, Director Rebecca M. Henderson sold 8,790 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $241.57, for a total transaction of $2,123,400.30. Following the completion of the sale, the director now owns 27,486 shares of the company’s stock, valued at $6,639,793.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Giovani Twigge sold 1,500 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $211.77, for a total transaction of $317,655.00. The disclosure for this sale can be found here. Insiders have sold 52,150 shares of company stock valued at $12,754,596 in the last ninety days. Insiders own 2.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Parsons Capital Management Inc. RI Decreases Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)” was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://sundanceherald.com/2019/05/22/idexx-laboratories-inc-idxx-shares-sold-by-parsons-capital-management-inc-ri.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: How does equity income fit into an investing strategy?

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply